We are comparing Five Prime Therapeutics Inc. (NASDAQ:FPRX) and Acer Therapeutics Inc. (NASDAQ:ACER) on their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings and Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Five Prime Therapeutics Inc.	49.87M	7.83	140.45M	-4.11	0.00
Acer Therapeutics Inc.	N/A	0.00	21.28M	-2.01	0.00

Table 1 highlights Five Prime Therapeutics Inc. and Acer Therapeutics Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows the return on assets, net margins and return on equity of the two firms.

	Net Margins	Return on Equity	Return on Assets
Five Prime Therapeutics Inc.	-281.63%	-44.6%	-36.9%
Acer Therapeutics Inc.	0.00%	-62.9%	-57.9%

Volatility and Risk

Five Prime Therapeutics Inc.’s current beta is 3.21 and it happens to be 221.00% more volatile than S&P 500. In other hand, Acer Therapeutics Inc. has beta of 2.57 which is 157.00% more volatile than S&P 500.

Liquidity

Five Prime Therapeutics Inc.’s Current Ratio and Quick Ratio are 10.5 and 10.5 respectively. The Current Ratio and Quick Ratio of its competitor Acer Therapeutics Inc. are 22 and 22 respectively. Acer Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to Five Prime Therapeutics Inc.

Analyst Ratings

Recommendations and Ratings for Five Prime Therapeutics Inc. and Acer Therapeutics Inc. can be find in next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Five Prime Therapeutics Inc.	0	0	2	3.00
Acer Therapeutics Inc.	0	0	1	3.00

Five Prime Therapeutics Inc.’s upside potential currently stands at 118.18% and an $24 consensus price target. Acer Therapeutics Inc. on the other hand boasts of a $40 consensus price target and a 79.86% potential upside. The results provided earlier shows that Five Prime Therapeutics Inc. appears more favorable than Acer Therapeutics Inc., based on analyst belief.

Insider and Institutional Ownership

Roughly 88.4% of Five Prime Therapeutics Inc. shares are owned by institutional investors while 59.3% of Acer Therapeutics Inc. are owned by institutional investors. Insiders owned 2.4% of Five Prime Therapeutics Inc. shares. Comparatively, 24.21% are Acer Therapeutics Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Five Prime Therapeutics Inc.	0.67%	7.11%	-6.3%	-14.3%	-41.5%	29.57%
Acer Therapeutics Inc.	1.7%	-2.41%	1.19%	-25.55%	37.99%	18.79%

For the past year Five Prime Therapeutics Inc.’s stock price has bigger growth than Acer Therapeutics Inc.

Summary

On 6 of the 10 factors Five Prime Therapeutics Inc. beats Acer Therapeutics Inc.

Acer Therapeutics Inc. develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease (MSUD). It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD). The company was founded in 2013 and is based in Cambridge, Massachusetts.